A novel interaction between HER2/neu and cyclin E in breast cancer.
about
Novel Molecular Markers for Breast CancerThe therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunityLMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patientsTaspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis.Association of germline variation in CCNE1 and CDK2 with breast cancer risk, progression and survival among Chinese Han womenCyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.Risk of severe diarrhea with dual anti-HER2 therapies: a meta-analysis.Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance.Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast CancerTarget points in trastuzumab resistanceInference of tumor phylogenies from genomic assays on heterogeneous samples.Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implicationsBreast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anticancer adaptive immune responseReinforcing targeted therapeutics with phenotypic stability factorsSuppression of FUT1 attenuates cell proliferation in the HER2-overexpressing cancer cell line NCI-N87Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients.Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006CDC25A protein stability represents a previously unrecognized target of HER2 signaling in human breast cancer: implication for a potential clinical relevance in trastuzumab treatment.Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast CancerHER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth.Novel multisample scheme for inferring phylogenetic markers from whole genome tumor profiles.Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells.HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer.The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.Emerging targeted agents in metastatic breast cancer.Why (multi)targeting of cyclin-dependent kinases is a promising therapeutic option for hormone-positive breast cancer and beyond.Cell membrane gp96 facilitates HER2 dimerization and serves as a novel target in breast cancer.Effects of ARHI on cell cycle progression and apoptosis levels of breast cancer cells.Growth hormone receptor (GHR) RNAi decreases proliferation and enhances apoptosis in CMT-U27 canine mammary carcinoma cell line.Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.Cell Cycle Regulation in Treatment of Breast Cancer.Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.
P2860
Q26753160-144857A7-0BA7-4CFB-A1D8-BC9E99FE0AE4Q34073138-744C0246-7C60-4D7E-B4B3-2028D02E3189Q34220979-555EF9F5-73F0-4DEF-9410-EB5C176B3A0AQ34452426-59363D66-B263-4258-92D6-CAF86D4D7B49Q34489947-077D0E6C-6466-400F-9424-BB05AC9C2B33Q34621219-ABEA2846-4193-4CB0-8477-23358E398543Q35077315-97C1A0C9-9706-4B3A-AAD0-BB2E142E69A2Q35624814-3DD505AD-65C0-4F05-A222-1BDB1A42205EQ35684440-5869865D-797C-4F0D-B0E3-0BDA902F8EFBQ35821286-150306B4-8CD8-47CD-A3C5-FD51A64549A1Q35986538-553EFB7A-E2C4-4F81-9CAE-DAE4EF1A3FD2Q36088788-33975D83-7A05-4E61-8B2F-695E8B12BBF0Q36096051-13AE5095-377C-438A-BBBC-22DA02E8A86BQ36187514-20101788-224C-480E-A4A2-6D020F3BF985Q36642333-81861760-601F-4D36-97D7-CAB62C01C78AQ36729467-CBBCC2A8-1065-4E6B-89FD-7A6858765DA1Q36810717-35158779-6B73-4B56-8AD7-9A20089A36F4Q36881905-DEA1EC19-C06B-44C9-9948-BC5E76D394CDQ37057171-B9E1C96F-B711-4046-8B84-C89CA0061A0FQ37269081-974AB864-174D-4BCC-8CA5-42FA96A68207Q37315891-63B8C392-ED04-4B3F-947C-4CEFCE206A7AQ37565022-A2887F07-463F-476A-85FE-848975FB8A0EQ37699133-02DDA5D9-5A48-421B-8577-78D70DD4F1A5Q37948079-1E5310ED-4700-4796-B8D3-3B70FE2F5DC7Q38086421-7F02C71D-31CA-49F6-BACF-50F6C8C035D0Q38675849-6D09E109-7106-44CE-AD3D-DBA8E8EFC7F4Q38924681-958467DD-6A25-495F-BE74-00A5743A2461Q39359785-22ED4204-AE82-413C-B826-76E6DD4978F2Q39413877-5A27290F-6FCA-46A8-B30C-0354A21E16E4Q40951473-EEA2FB48-3808-4372-A21C-B118867E0C56Q49544319-6874E3F9-70C0-4EB5-BB8D-0FCB2DC4E9E6Q49558301-B533C2E9-7A1A-434C-A174-A69335DA5B0BQ52955581-50815DFD-BDEA-4680-B841-36F9A82F9276
P2860
A novel interaction between HER2/neu and cyclin E in breast cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
A novel interaction between HER2/neu and cyclin E in breast cancer.
@ast
A novel interaction between HER2/neu and cyclin E in breast cancer.
@en
type
label
A novel interaction between HER2/neu and cyclin E in breast cancer.
@ast
A novel interaction between HER2/neu and cyclin E in breast cancer.
@en
prefLabel
A novel interaction between HER2/neu and cyclin E in breast cancer.
@ast
A novel interaction between HER2/neu and cyclin E in breast cancer.
@en
P2093
P2860
P356
P1433
P1476
A novel interaction between HER2/neu and cyclin E in breast cancer.
@en
P2093
A Biernacka
E A Mittendorf
K Keyomarsi
S L Tucker
T McKenzie
P2860
P2888
P304
P356
10.1038/ONC.2010.151
P407
P577
2010-05-10T00:00:00Z
P5875
P6179
1023175042